Otonomy Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 09, 2016 16:15 ET
|
Otonomy, Inc.
SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Present at Cowen and Company Health Care Conference
February 29, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy to Report Fourth Quarter and Full Year 2015 Financial Results and Provide Corporate Update
February 26, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 26, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
January 26, 2016 07:05 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
January 12, 2016 09:27 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 12, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311
October 05, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere's Disease
May 21, 2015 16:05 ET
|
Otonomy, Inc.
Narrowly missed primary endpoint of reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period, p = 0.067
Achieved statistical significance on...
Otonomy Appoints Eric Loumeau as General Counsel and Chief Compliance Officer
May 18, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports First Quarter 2015 Financial Results and Provides Corporate Update
May 12, 2015 16:01 ET
|
Otonomy, Inc.
SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro(TM) in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
May 07, 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, May 7, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...